MedTrace Logo

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

NCT06217666 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

PCX-12

treatment combining radiation therapy with PCX12

Sponsors & Collaborators

  • Haoming (Carl) Qiu

    lead OTHER

Principal Investigators

  • Haoming Qiu · University of Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2028-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06217666 on ClinicalTrials.gov